公开(公告)号：US11261254B1

公开(公告)日：2022-03-01

申请号：US17494545

申请日：2021-10-05

Applicant: GENMAB A/S

Inventor： Louise Koopman ,  Patrick Engelberts ,  Dennis Verzijl ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Sieto Bosgra ,  Frederikke L. Egerod ,  David Satijn ,  Esther C. W. Breij

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20210253725A1

公开(公告)日：2021-08-19

申请号：US17144591

申请日：2021-01-08

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US11008399B2

公开(公告)日：2021-05-18

申请号：US17077376

申请日：2020-10-22

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US10793640B2

公开(公告)日：2020-10-06

申请号：US15627921

申请日：2017-06-20

Applicant: GENMAB A/S

Inventor： Bart De Goeij ,  Edward N. Van Den Brink ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  David Satijn ,  Jan Van De Winkel ,  Paul Parren

IPC: C07K16/30 ,  A61K39/395 ,  C07K16/32 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US10765743B2

公开(公告)日：2020-09-08

申请号：US16248402

申请日：2019-01-15

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  A61K39/00 ,  C07K16/30

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20240400703A1

公开(公告)日：2024-12-05

申请号：US18660847

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11459395B2

公开(公告)日：2022-10-04

申请号：US17172694

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz ,  Edward Van den Brink ,  Dennis Verzijl

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US10968280B2

公开(公告)日：2021-04-06

申请号：US16779011

申请日：2020-01-31

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20200079866A1

公开(公告)日：2020-03-12

申请号：US16582534

申请日：2019-09-25

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US10544220B2

公开(公告)日：2020-01-28

申请号：US15541594

申请日：2016-01-08

Applicant: GENMAB A/S

Inventor： Patrick Engelberts ,  Esther Breij ,  Rik Rademaker ,  Isil Altintas ,  David Satijn ,  Sandra Verploegen ,  Riemke Van Dijkhuizen Radersma ,  Edward Van Den Brink ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K39/00

Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.